Business Wire

WORLD-VAPERS’-ALLIANCE

30.6.2021 00:32:10 CEST | Business Wire | Press release

Share
World Vapers’ Alliance: Back Vaping to Beat Smoking and to Save 200 Million Lives

The World Vapers’ Alliance is today launching a major global campaign – Back Vaping. Beat Smoking - with the goal of shaping international public health policies and saving 200 million lives worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629006043/en/

“The weight of research and real-world evidence shows that progressive vaping policies can help millions of smokers to quit. Yet vaping remains under threat as decision-makers face pressure from anti-vaping organisations. Our campaign will make sure the evidence and the voices of vapers are heard, so that Governments will take the opportunity to save 200 million lives”, said Michael Landl, Director of the World Vapers’ Alliance.

2021 is a critical year for public health policies globally. Two major milestones will determine if Governments grab the opportunity to save 200 million lives, or decide to limit smokers’ access to life-changing quit tools. The global ‘COP9’ conference will set the direction for anti-smoking and vaping policies worldwide. And the EU’s ‘Tobacco Products Directive’ laws, currently being discussed in Brussels, will act as the benchmark for vaping policies globally.

“There is a risk that global leaders at COP 9 and at EU level - under pressure from anti-vaping activists - will introduce laws that would treat vaping the same as smoking” according to Landl. “This would spell disaster for vapers, for smokers and for public health. Millions of vapers may be forced back to smoking due to tax hikes, flavour bans, and other restrictions on vaping accessibility.”

“If they ignore that vaping is 95% less harmful than smoking and has already helped millions to quit smoking, then they will miss a golden opportunity to save lives. Nearly 200 million lives can be saved if the right vaping policies are introduced, and 2021 is an absolutely critical year if this is to be achieved,” Michael Landl added.

The World Vapers’ Alliance is launching a global campaign today to make sure that the voices of the millions of vapers who have successfully beaten smoking thanks to vaping are heard. The Back Vaping. Beat Smoking campaign will deliver a clear message to all the decision-makers around the world: The best way we can beat smoking is to promote vaping as part of public health policies.

“It’s vital that vapers' voices are heard. That’s why we’re taking our campaign out on the road, across Europe and around the world. Our campaign will combine digital and real-world activism to ensure that Governments take the opportunity to ‘Back Vaping. Beat Smoking’,” Michael Landl concluded.

ENDS

---

Notes to editor:

  • The World Vapers’ Alliance represents 23 vapers associations as well as 14.000 individual vapers from all over the world.
  • Next FCTC COP9 meeting will be held 8–13 November 2021.
  • The European Commission’s report on assessing the application of the rules laid down in the Tobacco Products Directive 2014/40/EU (TPD) was published on 20 May 2021.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye